We also showed that citrullinated peptides, corresponding to these in vivo modified epitopes, can be used as targeting agents, blocking a significant portion of ACPA binding to CCP2, forming the basis of a possible future therapeutic approach for ACPA-positive RA. Here, PRTN3 is linked to rheumatoid arthritis.